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Vaccines for tick-borne diseases and
cost-effectiveness of vaccination: a
public health challenge to reduce the
diseases’ burden
Expert Rev. Vaccines 15(1), 5–7 (2016)
Tick-borne encephalitis (TBE) and Lyme borreliosis (LB) are tick-borne diseases
(TBDs), and both present an increasing burden worldwide. Vaccination as public
health intervention could be the most effective way to reduce this burden. TBE
vaccines are available, but vaccines against LB are still in the phase of development.
At the European level, TBE vaccines are likely under-administered to effectively
prevent the disease. Cost-effectiveness of vaccination is a helpful tool in the
decision making process to include novel vaccines in the national vaccination
program or to extend current programs, and its role is only increasing. Cost-
effectiveness studies on TBE vaccines have been performed in Slovenia, Sweden,
Finland and Estonia so far. Cost-effectiveness studies with the novel vaccines
against LB are expected to be performed in the near future.
Tick-borne diseases (TBDs) are one of
the most rapidly expanding infectious
diseases worldwide. Many new human
tick-borne pathogens are discovered and
several novel TBDs are recognized.
Therefore, TBDs’ burden may exceed
the currently estimated burden.[1]
TBDs are becoming an increasing public
health concern globally.[1]
Increasing burden of TBDs shows that
current available public health interven-
tions and approaches are not effective
enough. Vaccination could be a very
effective and highly cost-effective inter-
vention for preventing morbidity of the
TBDs.[1,2] Whereas vaccines against
Lyme borreliosis (LB) have not yet been
developed, vaccines against tick-borne
encephalitis (TBE) are available.
Development of TBDs’ vaccines faces
numerous difficulties and challenges
mainly due to diversity of human tick-
borne pathogens. Antigenic variations of
the LB spirochetes present an enormous
obstacle in developing LB vaccines,
inclusive the differences between LB
strains in Europe and the USA.[1]
However, recently huge progress in vac-
cine development has been seen for LB.
[3] At the moment, no human TBDs’
vaccines are licensed in the USA [1];
however, vaccines against TBE are
licensed for use in Europe and Russia.
[4] In 1998, one of two developed mono-
valent vaccines, based on outer surface
protein A (OspA), was licensed against
LB for the use only in the USA.[5] In
2002, this vaccine was withdrawn from
the USA market, mainly because of safety
concerns related to potential occurrence
of arthritis.[5] Currently, in Europe,
huge efforts focus on development of a
novel multivalent-based OspA vaccine.
The risk for occurrence of potential
arthritis with this novel vaccine seems
eliminated.[3] At the moment, this
novel vaccine potentially presents the
most effective future protection against
LB in the USA, Europe and Asia.[3]
Other LB vaccines that include proteins
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such as OspB, OspC or DNA-binding protein HU-alpha are in
different stages of development.[1] Also, various cocktails of
several borrelia outer membrane and tick proteins are potential
candidates for development of Lyme vaccines.[6] Tick proteins
may be used for the development of an anti-tick vaccine for
effective prevention not only against LB but also against other
human TBDs in Europe. Notably, vaccination with an anti-tick
vaccine could be a highly cost-effective public health interven-
tion that can reduce the burden of TBDs and therefore their
impact on the society.[2]
Cost-effectiveness is an important consideration nowadays
prior to introduction of large-scale vaccination. Cost-effective-
ness analysis (CEA) concerns an economic evaluation compar-
ing costs and health outcomes, mostly expressed in quality-
adjusted life years (QALYs), for vaccination versus no vaccina-
tion strategies. Results of CEAs are presented as incremental
cost-effectiveness ratios (ICERs). The ICER is calculated as the
difference in the cost of vaccination and no vaccination,
divided by the difference in the health outcomes produced
by vaccination and no vaccination. CEAs are supportive to
government national committees advising on vaccination stra-
tegies, such as the Dutch Health Council, UK’s Joint
Committee on Vaccination & Immunization, the Belgium
“Knowledge Center” and the “Ständigen Impfkommission” at
the German Robert Koch Institute, on optimal use and reim-
bursement of new or existing vaccines.
TBE can affect the central nervous system, which may
result in long-term/permanent neurological sequelae or even
death.[4] At the European level, TBE presents an increasing
public health concern with vaccination against TBE less
widely used than possible to reduce the disease burden.
Cost-effectiveness studies of TBE vaccines to support inclu-
sion/expansion of TBE vaccination in national vaccination
programs against TBE are needed. In 2012, the first study
on the cost-effectiveness of two licensed Western European
vaccines was published, using a Markov model.[7] The use of
the Markov model for evaluating the cost-effectiveness of
TBE vaccination was an innovation.[7] The Markov model
was developed on the basis of the natural course of the
disease.[7] Results were expressed in costs per QALY, show-
ing that vaccination of adults aged 18–80 is cost-effective
(inclusive boosters) from the view of the health care payer
and even cost saving from the societal perspective in Slovenia.
[7] The ICER for vaccination amounted to approximately
€15,000–20,000 per QALY gained from the view of the
health care payer.[7] The recognition of the importance of
this study [7] can be seen when considering its impact.
Firstly, in the Swedish county Sörmland, the County
Council used this Markov model for their decision about
TBE vaccination.[8] Results did not show favorable cost-
effectiveness for all ages.[8,9] Secondly, in Finland, the
cost-effectiveness study – using the same approach – showed
that vaccination brings economic savings from the health care
payer perspective with specific plausible assumptions on inci-
dence of the disease, and respiratory paralysis and on
duration of treatment.[10] When the incidence of cases of
respiratory paralysis would be reduced from 1/3 to 1/9 per
year at the same incidence of the disease and duration of
treatment, vaccination against TBE would still be cost-effec-
tive with an ICER at €16,000 per QALY gained from the
health care perspective.[10] Also, for lowered assumptions on
disease incidence, vaccination against TBE remained cost-
effective.[10] Only at an incidence of the disease below 5/
100,000, vaccination could become not cost-effective with an
ICER higher than €100,000 per QALY gained.[10] Based on
this cost-effectiveness study, the TBE immunization working
group in Finland made a recommendation on vaccination
against TBE.[10] Thirdly, an Estonian study [11] showed
that vaccination of the whole population comes with an
ICER of €61,000 per QALY gained, using a Markov
model. Vaccination against TBE for the population
≥50 years is more cost-effective, with an ICER of €25,000
per QALY gained from the health care perspective.
Next to the cost-effectiveness of vaccination against TBE in
Slovenia,[7] the burden for TBE was measured in disability-
adjusted life years (DALYs) for the same country, using the
updated DALYs methodology.[12,13] Notably, corrections for
under-estimation were taken into account.[12,13] The burden
of TBE was not previously expressed in DALYs. The burden
model was developed based on the health outcomes of the
natural course of the disease.[12,13] Results of the study showed
that total DALYs amount to 3,450 [12,13] presenting a relative
high burden as measured in DALYs compared with estimates for
other infectious diseases from the Global Burden of Disease
2010 study for Slovenia. High TBE burden presents a public
health challenge for more efficient policies and actions to reduce
TBE in Slovenia, inclusive of an extended vaccination campaign
in Slovenia. Taking into account the fact that in Slovenia and
various similar countries, likely very low vaccination coverage
exists,[14] ample room for improvement exists. Also, vaccina-
tion can add to a rising awareness about the disease that is
proposed to also currently reduce the burden of TBE.[12] In
Austria, it has been shown that extended TBE vaccination can
be beneficial from both the health and economic perspec-
tives.[15]
LB, the most common reported TBD, affects mostly the skin,
joints, nervous system and heart.[16] Especially if LB is left
untreated, it may lead to serious complications.[16] LB has even
been suggested to potentially also be deadly.[1] LB is an increasing
public health concern inmany parts of the USA, across Europe and
globally. Only in the USA, some studies on cost-effectiveness of
vaccination with monovalent OspA vaccine against LB were per-
formed, showing that the vaccine could be cost-effective at high
risks of infection.[17–19] However, no cost-effectiveness studies
with LB vaccines have been performed in Europe.[20]
CEA is crucial to support decision-making and guiding the
choices to be made in the allocation of resources, as well as to
determine strategic planning priorities. Further research on cost-
effectiveness of vaccines against TBDs is needed, in particular
regarding upcoming LB vaccines. Currently, such studies are
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being planned. With TBDs being a serious public health con-
cern, awareness of TBDs and increasing knowledge about TBDs
among the general population remain important. Increasing
investment in research, development and implementation of
novel TBDs vaccines can crucially add to this, to further reduce
the diseases’ burden and ultimately lead to substantial health
benefits and financial returns.
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